|
KMID : 0391520120200030164
|
|
Journal of the Korean Child Neurology Society
2012 Volume.20 No. 3 p.164 ~ p.169
|
|
|
Efficacy and Tolerability of Rufinamide for Intractable Generalized Epilepsies
|
|
Yoo Il-Han
Hong Won-Gi
Kim Jon-Soo
Ryu Hye-Won
Byun Sung-Hwan
Kim Hun-Min
Lim Byung-Chan
Chae Jong-Hee
Choi Ji-Eun
Kim Ki-Joong
Hwang Yong-Seung
Hwang Hee
|
|
|
Abstract
|
|
|
Purpose: The purpose of the study was to evaluate the efficacy and safety of rufinamide for intractable generalized epilepsies.
Methods: Eighteen patients with intractable generalized epilepsies were included in the study. Their medical records were retrospectively reviewed. Rufinamide was administered as an add-on treatment for intractable epilepsies. The initial administered dose was 10 mg/kg/day, which was subsequently titrated up to 30-50 mg/kg/day. The effectiveness was assessed by comparing the frequency of seizures after the treatment. The difference in number of seizures during 4 weeks was compared before and after reaching the final dose.
Results: The study population consisted of 13 males and 5 females (mean age 13.6+/-6.2 years, range 3.3-29.2 years). The responder rate (> or =50% in seizure frequency) was 39% and the seizure free rate was 11%. Retention rate was 44% and the reasons for withdrawal was adverse events (6/18 patients, 33%), aggravation of seizures (4/18 patients, 22%), and ineffectiveness (2/18 patients, 11%). Adverse events included hyperactivity, somnolence, ataxia and polyhidrosis. Adverse events and seizure aggravation occurred even at the starting dose of rufinamide treatment.
Conclusion: Rufinamide can be used as an efficacious and safe adjunctive anticonvulsant for patients with intractable generalized epilepsy.
|
|
|
KEYWORD
|
|
|
Rufinamide, Efficacy, Adverse event, Seizure, Generalized
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|